A 2-part Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled, Ascending Dose and Parallel Group Study of TLR4 Agonist (GSK1795091) Administered to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2017
At a glance
- Drugs GSK 1795091 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 22 Nov 2017 Status changed from recruiting to completed.
- 03 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 19 Sep 2017.
- 10 Jun 2017 Biomarkers information updated